2005

1-20 of 244 < first | prev | | last >
  • PAT in Perspective: Estimate PAT’s Real Costs

    Don’t be “penny-wise but pound-foolish” during early planning and budgeting stages, and never base decisions on equipment sticker prices without considering savings in time to market.

    Emil W. Ciurczak, Chief Technical Officer, Cadrai Group
    12/20/2005
  • Proactive Ergonomics

    Progressive programs at Pfizer, AstraZeneca, Johnson & Johnson and Biogen Idec are raising the bar for pharmaceutical manufacturing.

    Barbara F. Taylor, CIH, Director of EHS, Biogen Idec, and Rachel Michael, M.Sc., AEP, Assistant Vice President, Marsh Risk Consulting
    12/16/2005
  • Peter Rost: Hero or Whiner? You Decide

    Former Pfizer executive Peter Rost has taken the moral high ground in the past, and brought welcome objectivity to the debate over drug importation. The talented executive could easily find a post in a public policy arena, so why is he suing his former employer — one he has criticized for years — for wrongful termination?

    12/15/2005
  • New Ideas Hatch in Process Development

    Don’t expect pilot plants to disappear as better tools and techniques enhance efforts.

    Mike Spear, editor at large, ChemicalProcessing.com
    12/09/2005
  • RFID Standards and Drug Security in the Year Ahead

    Neither UHF nor HF is going to be a slam dunk for e-pedigrees. RFID development will be similar to that of bar coding. AIM Global's Bert Moore provides an update on standards and research into how radio frequency impacts drug product.

    Bert Moore, IDAT Consulting, AIM Global
    12/07/2005
  • Making the Most of Drug Development Data

    Improving time to market requires finding — and sharing — the right information at the right time. A benchmarking survey reveals that pharma and biopharma still have a long way to go.

    Ken Morris, Ph.D., associate head of Industrial and Physical Pharmacy, Purdue University, with Sam Venugopal, director, Life Science Business Operations, Conformia Software, Inc. and Michael Eckstut, vice president, Life Science Operations, Conformia Soft
    12/01/2005
  • Cost-Driven Chromatography

    Economics is driving bioseparations that minimize waste and maximize output, and moving continuous chromatography into some small-molecule niches.

    Angelo De Palma, Ph.D., Contributing Editor
    12/01/2005
  • Making the Most of Drug Development Data

    Improving time to market requires finding — and sharing — the right information at the right time. A benchmarking survey reveals that pharma and biopharma still have a long way to go.

    Ken Morris, Ph.D., associate head of Industrial and Physical Pharmacy, Purdue University, with Sam Venugopal, director, Life Science Business Operations, Conformia Software, Inc. and Michael Eckstut, vice president, Life Science Operations, Conformia Soft
    12/01/2005
1-20 of 244 < first | prev | | last >